Skip to main content
大唐药业 logo

大唐药业 — Investor Relations & Filings

Ticker · 920433 Beijing Stock Exchange Manufacturing
Filings indexed 420 across all filing types
Latest filing 2026-04-28 Annual Report
Country CN China
Listing Beijing Stock Exchange 920433

About 大唐药业

http://www.nmdt.com.cn/

Inner Mongolia Datang Pharmaceutical specializes in the research, development, and production of traditional Chinese and Mongolian medicines. The company focuses on modernizing ethnic medicinal formulas through advanced biotechnology and standardized manufacturing processes. Its product portfolio covers therapeutic areas including respiratory health, cardiovascular conditions, and gastrointestinal disorders. Notable offerings include Xuanfei Zhike granules and specialized Mongolian medicinal preparations. The organization integrates traditional knowledge with contemporary clinical research to develop proprietary formulations. By maintaining rigorous quality management systems and investing in automated production lines, the company aims to enhance the efficacy and accessibility of ethnic medicines for a broad patient base.

Recent filings

Filing Released Lang Actions
2025年年度报告
Annual Report Classification · 100% confidence The document is titled "内蒙古大唐药业股份有限公司2025年年度报告" which translates to "Inner Mongolia Grand Pharmaceutical Co., Ltd. 2025 Annual Report." It contains detailed financial data, including profit and loss statements, balance sheet items, quarterly financial data, management discussion and analysis, company overview, risk factors, and other comprehensive information typical of a full annual report. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes audited financial statements and an auditor's opinion, confirming it is the official annual report. Therefore, the document fits the definition of an Annual Report (10-K). FY 2025
2026-04-28 Chinese
关于取得发明专利证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement about obtaining an invention patent certificate, including details about the patent and its impact on the company. It is a regulatory announcement related to intellectual property rights and does not contain financial data, management changes, voting results, or other report types. The document length is short (681 characters) and it is clearly an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2026-02-26 Chinese
2025年年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2025 Annual Performance Express Report" and contains preliminary financial data for the full fiscal year 2025, including revenue, profit, net assets, and earnings per share. It explicitly states that the data are preliminary and unaudited, with final audited figures to be disclosed in the full 2025 Annual Report. The document is relatively short (2048 characters) and serves as a quick earnings summary or performance update rather than a full annual report. It includes key financial metrics and explanations of performance changes but lacks comprehensive audited financial statements or detailed management discussion typical of a full Annual Report (10-K). Therefore, this document fits the definition of an Earnings Release (ER), which is an initial announcement of yearly financial results with key highlights only, not the full report itself. FY 2025
2026-02-26 Chinese
2025年年度业绩预告公告
Earnings Release Classification · 95% confidence The document is an announcement of the company's preliminary annual performance forecast for the fiscal year 2025, including estimated net profit and explanations for changes. It explicitly states that the financial data are preliminary, unaudited, and subject to the final audited annual report. The document length is short (1064 characters) and it does not contain full financial statements or detailed financial analysis. It serves as a performance forecast announcement rather than the full Annual Report (10-K). Therefore, it fits best into the category of Earnings Release (ER), which covers initial announcements of quarterly or annual financial results highlights. FY 2025
2026-01-28 Chinese
股东减持股份结果公告
Transaction in Own Shares Classification · 95% confidence The document is a shareholder announcement regarding the results of a shareholding reduction (shareholder selling shares). It details the shareholder's name, shareholding before and after reduction, the number of shares reduced, the method, period, and price range of the reduction. It is not a financial report, earnings release, or management discussion. It is a notification about a transaction in own shares by a significant shareholder. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is short and contains detailed data about the share reduction, not just an announcement of a report publication or regulatory filing. Hence, the classification is POS with high confidence.
2025-12-17 Chinese
对外捐赠公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from a company about an external donation of pharmaceutical products to a charitable organization. It includes assurances about the accuracy of the announcement and states that the donation does not require board or shareholder approval and does not affect company performance materially. There is no financial report, no regulatory filing about financial results, no management or board changes, no voting results, no capital changes, and no legal proceedings. The document is a standalone announcement about a corporate social responsibility action, which does not fit into the specific financial or regulatory report categories. It is a general regulatory announcement about a corporate event that does not fit other categories, so it falls under Regulatory Filings (RNS). The document length is short and it is not a report publication announcement or certification. Therefore, the best classification is Regulatory Filings (RNS) with high confidence.
2025-12-17 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.